Optimal first-line immune checkpoint inhibitor treatment in lung cancer: how to choose?

Future Oncol. 2022 Feb;18(6):635-638. doi: 10.2217/fon-2021-1348. Epub 2022 Jan 12.

Authors

Adi Kartolo¹, Andrew Robinson¹, Andrea S Fung¹

Affiliation

¹ Division of Medical Oncology, Department of Oncology, Queen's University, Kingston, ON, K7L 3N6, Canada.

PMID: 35018801
DOI: 10.2217/fon-2021-1348

No abstract available

Keywords: chemotherapy; immunotherapy; metastatic; non-small-cell lung cancer; treatment choice.

Publication types

Editorial

MeSH terms

Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / pathology
Clinical Decision-Making*
Humans
Immune Checkpoint Inhibitors / therapeutic use*
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Neoplasm Metastasis

Substances

Immune Checkpoint Inhibitors